Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3233671 | 0.91 | CES2 (0.47) | NOS2CES2CES1MGLLKMT2A | |
| SCHEMBL1317993 | 0.87 | CES2 (0.53) | NOS2CES2CES1MGLLHDAC8 | |
| SCHEMBL3227064 | 0.87 | CES2 (0.53) | NOS2CES2CES1MGLLHDAC8 | |
| SCHEMBL28990391 | 0.87 | CES2 (0.53) | NOS2CES2CES1MGLLHDAC8 | |
| SCHEMBL2531344 | 0.87 | CES2 (0.53) | NOS2CES2CES1MGLLHDAC8 | |
| SCHEMBL3231716 | 0.87 | CES2 (0.53) | NOS2CES2CES1MGLLHDAC8 | |
| SCHEMBL3224880 | 0.87 | CES2 (0.53) | NOS2CES2CES1MGLLHDAC8 | |
| SCHEMBL6250105 | 0.84 | CES2 (0.50) | NOS2CES2CES1MGLLHDAC8 | |
| SCHEMBL8724596 | 0.70 | — | — | |
| SCHEMBL16964023 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352453-B2 | Catalyst for olefin polymerization and production method for polar group-containing olefin-based polymers | THE UNIVERSITY OF TOKYO (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20200347159-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND PRODUCTION METHOD FOR POLAR GROUP-CONTAINING OLEFIN-BASED POLYMERS | THE UNIVERSITY OF TOKYO (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3708593-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND PRODUCTION METHOD FOR POLAR GROUP-CONTAINING OLEFIN-BASED POLYMERS | The University Of Tokyo (JP) | 2020-09-16 | — | — | EP | disclosed |
| US-20140221472-A1 | USE OF MYRICETIN OR DERIVATIVES THEREOF AS A CATHEPSIN K INHIBITOR | JILINSHENG JINZIYUAN BIOTECHNOLOGY LTD (CN) | 2014-08-07 | — | — | US | disclosed |
| EP-2762137-A1 | Use of myricetin or derivatives thereof as a cathepsin k inhibitor | Jilinsheng Jinziyuan Biotechnology Ltd. (CN) | 2014-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347159-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND PRODUCTION METHOD FOR POLAR GROUP-CONTAINING OLEFIN-BASED POLYMERS | POF1B, COG1, ACOX1 | NOS2 510/4885CES2 1942/4885CES1 1209/4885 |
| US-20140221472-A1 | USE OF MYRICETIN OR DERIVATIVES THEREOF AS A CATHEPSIN K INHIBITOR | CTSK, CTSB, CTSV | NOS2 3115/4885CES2 1270/4885CES1 524/4885 |
| US-11352453-B2 | Catalyst for olefin polymerization and production method for polar group-containing olefin-based polymers | POF1B, COG1, ACOX1 | NOS2 510/4885CES2 1942/4885CES1 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.